Trade Names:Pataday- Solution, ophthalmic 0.2%
Trade Names:Patanase- Nasal Spray 0.6%
Trade Names:Patanol- Solution, ophthalmic 0.1%
Inhibits release of histamine from mast cells and relatively selective histamine H 1 antagonist. Inhibits type 1 immediate hypersensitivity reactions.
T max is 30 to 60 min; C max is 16 ng/mL; average absolute bioavailability is 57% (intranasal).
Protein binding is approximately 55%.
Not extensively metabolized.
Plasma elimination half-life is 3 h (ophthalmic) and 8 to 12 h (intranasal), mainly through urinary excretion.
Mean plasma AUC 0-12 is 2-fold higher. No dosage adjustment is required.Hepatic Function Impairment
Effects have not been established.Gender
C max and AUC were 40% and 27% higher, respectively, in women compared with men (intranasal).
Temporary relief of itching caused by allergic conjunctivitis (ophthalmic); temporary relief of symptoms of seasonal allergic rhinitis (intranasal).
Ophthalmic 1 to 2 drops in affected eye(s) twice daily, 6 to 8 h apart (0.1% solution). 1 drop in affected eye(s) once daily (0.2% solution). If using other topical ophthalmic drugs, separate each medication by 5 min or more.Adults and Children 12 yr of age and older
Intranasal 2 sprays per nostril twice daily.
Store between 39° and 77°F. Keep bottle tightly closed. Discard nasal spray after 240 sprays have been used.
Avoid concurrent use (intranasal).
None well documented.
Headache (7%); asthenia (5% or less); malaise (postmarketing); somnolence.
Bitter taste (13%); abdominal pain, diarrhea, nausea, thirst (postmarketing); taste perversion, nausea.
UTI (1%); occult blood in urine (postmarketing).
Blurred vision; burning, dry eye, foreign body sensation, hyperemia, keratitis, lid edema, pruritus, stinging (5% or less).
Abnormal hepatic function, increased cholesterol, WBC disorders (postmarketing).
Pharyngitis (10%); pharyngolaryngeal pain (2%); cough (1%).
Epistaxis (19%); nasal ulceration (9%); postnasal drip (2%); rhinitis, sinusitis.
Cold syndrome, dysgeusia.
Preform nasal examinations periodically (intranasal)
Category C .
Safety and effectiveness in children younger than 3 yr of age are not established (ophthalmic); safety and effectiveness in children younger than 12 yr of age not established (intranasal).
No differences in safety or effectiveness observed; however, use caution in dose selection, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Copyright © 2009 Wolters Kluwer Health.